Your browser is no longer supported. Please, upgrade your browser.
AVRO AVROBIO, Inc. monthly Stock Chart
AVRO [NASD]
AVROBIO, Inc.
Index- P/E- EPS (ttm)-3.30 Insider Own2.45% Shs Outstand36.44M Perf Week-17.37%
Market Cap620.69M Forward P/E- EPS next Y-3.46 Insider Trans0.00% Shs Float35.56M Perf Month-3.97%
Income-114.20M PEG- EPS next Q-0.88 Inst Own- Short Float8.51% Perf Quarter-19.37%
Sales- P/S- EPS this Y-30.30% Inst Trans1.10% Short Ratio12.61 Perf Half Y-32.90%
Book/sh5.70 P/B2.46 EPS next Y0.00% ROA-47.60% Target Price- Perf Year-13.29%
Cash/sh4.96 P/C2.83 EPS next 5Y- ROE-51.30% 52W Range9.76 - 29.32 Perf YTD-30.30%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-52.15% Beta-
Dividend %- Quick Ratio9.10 Sales past 5Y- Gross Margin- 52W Low43.75% ATR1.19
Employees123 Current Ratio9.10 Sales Q/Q- Oper. Margin- RSI (14)43.63 Volatility5.02% 7.93%
OptionableYes Debt/Eq0.00 EPS Q/Q-78.30% Profit Margin- Rel Volume1.34 Prev Close14.00
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume239.97K Price14.03
Recom1.80 SMA20-8.75% SMA50-7.03% SMA200-16.40% Volume322,633 Change0.21%
Nov-11-20Initiated Berenberg Buy
Mar-31-20Downgrade H.C. Wainwright Buy → Neutral $13
Jun-27-19Initiated Mizuho Buy $28
Apr-05-19Initiated Janney Buy
Oct-10-18Initiated Guggenheim Buy
Oct-02-18Reiterated H.C. Wainwright Buy $47 → $40
Sep-17-18Initiated H.C. Wainwright Buy $47
Jul-16-18Initiated Wells Fargo Outperform $40
Jul-16-18Initiated Wedbush Outperform $38
Jul-16-18Initiated Morgan Stanley Overweight $37
Nov-24-20 04:19PM  
Nov-19-20 10:06PM  
04:09PM  
Nov-17-20 07:00AM  
Nov-06-20 07:00AM  
Nov-05-20 07:00AM  
06:18AM  
Oct-29-20 07:00AM  
Oct-26-20 07:00AM  
Oct-21-20 07:00AM  
Oct-06-20 07:00AM  
Oct-05-20 07:00AM  
Sep-29-20 10:48AM  
Sep-28-20 07:00AM  
Sep-25-20 07:00AM  
Sep-04-20 07:00AM  
Sep-03-20 07:00AM  
Aug-12-20 09:41AM  
Aug-07-20 07:00AM  
Aug-06-20 07:00AM  
Aug-05-20 07:00AM  
Jul-27-20 08:23AM  
Jul-08-20 07:00AM  
Jul-06-20 07:00AM  
Jun-29-20 07:00AM  
Jun-24-20 04:16PM  
May-14-20 07:00AM  
May-13-20 07:00AM  
May-09-20 08:36AM  
May-08-20 08:42AM  
May-07-20 07:00AM  
May-06-20 04:05PM  
07:00AM  
May-05-20 07:00AM  
May-04-20 07:00AM  
Apr-14-20 08:58AM  
Apr-12-20 02:26PM  
02:26PM  
Apr-03-20 07:00AM  
Mar-30-20 04:30PM  
02:10PM  
Mar-26-20 07:00AM  
Mar-25-20 07:47PM  
07:00AM  
Mar-19-20 12:00PM  
Mar-17-20 05:58PM  
01:57PM  
12:53PM  
12:25PM  
Mar-16-20 07:00AM  
Mar-09-20 07:00AM  
Mar-05-20 07:00AM  
Feb-24-20 07:00AM  
Feb-18-20 04:01PM  
Feb-12-20 10:08PM  
04:01PM  
Feb-11-20 07:23AM  
Feb-10-20 04:01PM  
Feb-06-20 07:00AM  
Feb-04-20 07:00AM  
Jan-14-20 07:00AM  
Jan-09-20 04:00PM  
Dec-19-19 08:00AM  
Dec-16-19 08:00AM  
Dec-14-19 07:47PM  
Nov-07-19 07:00AM  
Nov-06-19 02:31PM  
Oct-24-19 07:00AM  
Oct-22-19 07:00AM  
Oct-16-19 06:02AM  
Oct-08-19 07:00AM  
Oct-03-19 08:00AM  
Sep-27-19 09:00AM  
Sep-11-19 10:22AM  
Aug-29-19 07:00AM  
Aug-16-19 08:30AM  
Aug-12-19 05:36PM  
Aug-08-19 07:00AM  
04:02AM  
Aug-06-19 08:00AM  
Jul-29-19 08:08AM  
Jul-26-19 07:51AM  
Jul-19-19 04:01PM  
Jul-18-19 05:57AM  
Jul-17-19 04:26PM  
12:35PM  
Jul-16-19 09:58PM  
04:01PM  
Jul-15-19 04:28PM  
07:00AM  
May-13-19 07:00AM  
May-12-19 06:43PM  
Apr-29-19 07:00AM  
Apr-26-19 04:00PM  
Mar-25-19 07:00AM  
Mar-05-19 07:00AM  
Feb-06-19 09:00AM  
Feb-05-19 02:48PM  
Feb-01-19 07:00AM  
Jan-18-19 07:43AM  
AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company has a research and clinical collaboration agreement with Magenta Therapeutics to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MACKAY GEOFFREYSee RemarksFeb 12Sale29.071,40040,692345,123Feb 14 07:16 PM
PAIGE CHRISTOPHERDirectorFeb 11Sale28.0015,000420,000252,512Feb 11 09:26 PM
MACKAY GEOFFREYSee RemarksFeb 11Sale27.5763,0001,737,081346,523Feb 11 09:23 PM
PAIGE CHRISTOPHERDirectorJan 28Sale23.0010,000230,000267,512Jan 30 04:10 PM